Loading clinical trials...
Loading clinical trials...
Phase 1b Randomized, Double Blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 in Patients With Atopic Dermatitis and Psoriasis
Conditions
Interventions
LPX-TI641
Placebo
Locations
3
United States
Red River Research Partners
Fargo, North Dakota, United States
Clinical Investigations of Texas
Dallas, Texas, United States
Triumpharma Clinical Research Unit at AlEssra Hospital
Amman, Jordan, Jordan
Start Date
June 15, 2025
Primary Completion Date
January 15, 2026
Completion Date
April 15, 2026
Last Updated
December 19, 2025
NCT07298395
NCT06928246
NCT07316465
NCT07235384
NCT07259343
NCT07233291
Lead Sponsor
LAPIX Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions